These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35311150)

  • 1. Identification and Validation of N6-Methyladenosine-Related Biomarkers for Bladder Cancer: Implications for Immunotherapy.
    Deng H; Tang F; Zhou M; Shan D; Chen X; Cao K
    Front Oncol; 2022; 12():820242. PubMed ID: 35311150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer.
    Liu J; Wang J; Wu M; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
    Front Med (Lausanne); 2021; 8():757432. PubMed ID: 35004726
    [No Abstract]   [Full Text] [Related]  

  • 3. RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells.
    Tsuruta N; Tsuchihashi K; Ohmura H; Yamaguchi K; Ito M; Ariyama H; Kusaba H; Akashi K; Baba E
    Biochem Biophys Res Commun; 2020 Sep; 530(1):235-239. PubMed ID: 32828292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression.
    Song W; Yang K; Luo J; Gao Z; Gao Y
    Aging (Albany NY); 2021 Jan; 13(3):3909-3925. PubMed ID: 33461172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. m
    Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
    Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy.
    Guo L; Yang H; Zhou C; Shi Y; Huang L; Zhang J
    Front Immunol; 2021; 12():773570. PubMed ID: 34956201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA N6-Methyladenosine Regulator-Mediated Methylation Modifications Pattern and Immune Infiltration Features in Glioblastoma.
    Pan Y; Xiao K; Li Y; Li Y; Liu Q
    Front Oncol; 2021; 11():632934. PubMed ID: 33718217
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Mo P; Xie S; Cai W; Ruan J; Du Q; Ye J; Mao J
    J Int Med Res; 2020 Sep; 48(9):300060520951405. PubMed ID: 32972288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FTO promotes the progression of bladder cancer via demethylating m
    Wu N; Sun Y; Xue D; He X
    Heliyon; 2024 Jul; 10(14):e34031. PubMed ID: 39100467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTO plays a crucial role in gastrointestinal cancer and may be a target for immunotherapy: an updated review.
    Ren X; Tang X; Huang T; Hu Z; Wang Y; Zhou Y
    Front Oncol; 2023; 13():1241357. PubMed ID: 37916161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N
    Quan C; Belaydi O; Hu J; Li H; Yu A; Liu P; Yi Z; Qiu D; Ren W; Ma H; Gong G; Ou Z; Chen M; Sun Y; Chen J; Zu X
    Front Immunol; 2021; 12():697026. PubMed ID: 34526985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N6-methyladenosine Regulator-Mediated Immune Genes Identify Breast Cancer Immune Subtypes and Predict Immunotherapy Efficacy.
    Zhang MM; Lin YL; Zeng WF; Li Y; Yang Y; Liu M; Ye YJ; Jiang KW; Wang S; Wang S
    Front Genet; 2021; 12():790888. PubMed ID: 34976022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tumor-suppressive effects of alpha-ketoglutarate-dependent dioxygenase FTO via N6-methyladenosine RNA methylation on bladder cancer patients.
    Yi W; Yu Y; Li Y; Yang J; Gao S; Xu L
    Bioengineered; 2021 Dec; 12(1):5323-5333. PubMed ID: 34499008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M
    Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L
    Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. m
    Sun M; Xie M; Zhang T; Wang Y; Huang W; Xia L
    Front Immunol; 2021; 12():739768. PubMed ID: 34616403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.
    Wu Z; Zhang X; Chen D; Li Z; Wu X; Wang J; Deng Y
    Front Immunol; 2021; 12():806189. PubMed ID: 35095893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging roles and mechanism of N6-methyladenosine (m
    Zhu W; Zhao R; Guan X; Wang X
    Front Pharmacol; 2023; 14():1192495. PubMed ID: 37284313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.